Neurocrine Biosciences (NBIX) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Product Sales: Exceeded $2.8 billion, a 22% year-over-year increase.

INGREZZA Revenue: Generated over $2.5 billion, up 9% year-over-year, driven by double-digit volume growth but impacted by pricing concessions for formulary access.

CRENESSITY Revenue: Achieved over $300 million in net sales in its first full year, capturing approximately 10% of the addressable patient population.

Cash Position: Increased to $2.5 billion from $1.8 billion at the end of 2024.

Non-GAAP Operating Margin: Approximately 30%, translating to about $850 million in operating income for 2025.

2026 Guidance for INGREZZA: Expected sales between $2.7 billion and $2.8 billion, indicating about 10% growth, with volume growth expected to offset pricing declines.

2Strategic Updates and Business Highlights

INGREZZA: Continues to show strong performance with a significant market opportunity as only 10% of the tardive dyskinesia (TD) population is currently treated with VMAT2 inhibitors.

CRENESSITY: Strong initial launch with positive feedback from prescribers and patients. The company aims to establish it as the standard of care for congenital adrenal hyperplasia (CAH).

Pipeline Development: Focus on advancing next-generation VMAT2 inhibitors and CRF-based therapies, with several late-stage programs in neuropsychiatry expected to yield data in 2027.

Sales Force Expansion: Planned expansion of the CRENESSITY sales team to enhance outreach and education efforts among prescribers, particularly in endocrinology and other specialties.

3Forward Guidance and Outlook

2026 Expectations: Anticipated continued growth for both INGREZZA and CRENESSITY, with a focus on maximizing revenue and advancing the pipeline.

R&D Investments: Increased R&D expenses anticipated due to ongoing Phase III trials and new program initiations, with expectations of maintaining a strong operating income.

Market Dynamics: The company is preparing for formulary negotiations in 2027, with a strategy to maintain favorable coverage and pricing stability.

4Bad News, Challenges, or Points of Concern

Pricing Pressure: INGREZZA faces a projected 4% decline in net pricing due to formulary access improvements, which may impact revenue growth.

Market Penetration: Despite strong initial uptake, only 10% of the CAH patient population is currently on CRENESSITY, indicating a significant opportunity but also a challenge in reaching broader adoption.

Seasonality and Patient Dynamics: Uncertainty regarding patient enrollment patterns and potential seasonality effects on new patient starts for CRENESSITY, as the company has yet to establish a clear trend.

Competitive Landscape: Concerns about future competition from investigational drugs, including ACTH antagonists, though management remains confident in CRENESSITY's differentiated profile.

5Notable Q&A Insights

Patient Dynamics for CRENESSITY: Management acknowledged that many prescribers have only treated one patient, indicating a need for ongoing education and outreach to drive further adoption.

Receptor Occupancy Data: Recent head-to-head data showed INGREZZA's superior VMAT2 target occupancy compared to AUSTEDO, which may enhance its competitive position.

Sales Force Expansion: The expansion aims to deepen engagement with existing prescribers and reach new prescribers, particularly in primary care settings.

Long-Term Pipeline: The company is optimistic about its ability to deliver new medicines every two years, with a robust pipeline expected to generate significant data in the coming years. Overall, Neurocrine Biosciences is positioned for continued growth in 2026, driven by strong performance from INGREZZA and a promising launch of CRENESSITY, despite facing challenges related to pricing pressures and market penetration.